Soparkar Peter 4

Accession 0001415889-25-017867

CIK 0001501756other

View on SEC.gov Company Profile

Filed

Jun 19, 8:00 PM ET

Accepted

Jun 20, 4:29 PM ET

Size

49.0 KB

Accession

0001415889-25-017867

Insider Transaction Report

Form 4

Period: 2025-06-17

Adverum Biotechnologies, Inc.ADVM

Soparkar Peter

CHIEF OPERATING OFFICER

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2025-06-17−40,000→ 0 total
Exercise: $68.80Exp: 2029-10-29→ Common Stock (40,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-06-17−13,000→ 0 total
Exercise: $12.90Exp: 2032-03-07→ Common Stock (13,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-06-17−16,384→ 0 total
Exercise: $10.90Exp: 2032-09-13→ Common Stock (16,384 underlying)
Award
Stock Option (Right to Buy)
2025-06-17+40,000→ 40,000 total
Exercise: $10.14Exp: 2029-10-29→ Common Stock (40,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-06-17−4,074→ 0 total
Exercise: $157.50Exp: 2030-02-19→ Common Stock (4,074 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-06-17−13,999→ 0 total
Exercise: $134.40Exp: 2031-02-15→ Common Stock (13,999 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-06-17−15,999→ 0 total
Exercise: $24.80Exp: 2031-08-05→ Common Stock (15,999 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-06-17−25,500→ 0 total
Exercise: $12.90Exp: 2032-03-07→ Common Stock (25,500 underlying)
Award
Stock Option (Right to Buy)
2025-06-17+13,000→ 13,000 total
Exercise: $10.14Exp: 2032-03-07→ Common Stock (13,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-06-17−45,000→ 0 total
Exercise: $19.90Exp: 2034-02-11→ Common Stock (45,000 underlying)
Award
Stock Option (Right to Buy)
2025-06-17+15,999→ 15,999 total
Exercise: $10.14Exp: 2031-08-05→ Common Stock (15,999 underlying)
Award
Stock Option (Right to Buy)
2025-06-17+25,500→ 25,500 total
Exercise: $10.14Exp: 2032-03-07→ Common Stock (25,500 underlying)
Award
Stock Option (Right to Buy)
2025-06-17+23,092→ 23,092 total
Exercise: $10.14Exp: 2032-09-13→ Common Stock (23,092 underlying)
Award
Stock Option (Right to Buy)
2025-06-17+13,999→ 13,999 total
Exercise: $10.14Exp: 2031-02-15→ Common Stock (13,999 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-06-17−23,092→ 0 total
Exercise: $10.90Exp: 2032-09-13→ Common Stock (23,092 underlying)
Award
Stock Option (Right to Buy)
2025-06-17+16,384→ 16,384 total
Exercise: $10.14Exp: 2032-09-13→ Common Stock (16,384 underlying)
Award
Stock Option (Right to Buy)
2025-06-17+4,074→ 4,074 total
Exercise: $10.14Exp: 2030-02-19→ Common Stock (4,074 underlying)
Award
Stock Option (Right to Buy)
2025-06-17+45,000→ 45,000 total
Exercise: $10.14Exp: 2034-02-11→ Common Stock (45,000 underlying)

Footnotes (13)

[F1]Effective March 21, 2024, the Issuer effected a reverse stock split (the "Reverse Split") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten.
[F10]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on September 14, 2022.
[F11]The options vest in equal monthly installments over three years from September 14, 2022, such that all of the shares subject to the option shall become vested and exercisable as of September 14, 2025, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.
[F12]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on February 12, 2024.
[F13]Twenty-five percent (25%) of the total number of shares subject to the option vested and became exercisable on the first anniversary of February 12, 2024, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of February 12, 2028, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.
[F2]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on October 30, 2019 and is fully vested.
[F3]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on February 20, 2020 and is fully vested.
[F4]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on February 16, 2021 and is fully vested.
[F5]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on August 6, 2021 and is fully vested.
[F6]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on March 8, 2022.
[F7]Twenty-five percent (25%) of the total number of shares subject to the option vested and became exercisable on the first anniversary of February 18, 2022, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of February 18, 2026, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.
[F8]The options vest in equal monthly installments over two years from August 16, 2023, such that all of the shares subject to the option shall become vested and exercisable as of August 16, 2025, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.
[F9]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on September 14, 2022 and is fully vested.

Documents

1 file

4
form4-06202025_080643.xmlPrimary

Issuer

Adverum Biotechnologies, Inc.

CIK 0001501756

→

Entity typeother

Related Parties

filerCIK 0001736315

Filing Metadata

Form type: 4
Filed: Jun 19, 8:00 PM ET
Accepted: Jun 20, 4:29 PM ET
Size: 49.0 KB

View on SEC.gov